[go: up one dir, main page]

GB0423953D0 - Pharmaceutical composition containing botulinum neurotoxin - Google Patents

Pharmaceutical composition containing botulinum neurotoxin

Info

Publication number
GB0423953D0
GB0423953D0 GBGB0423953.9A GB0423953A GB0423953D0 GB 0423953 D0 GB0423953 D0 GB 0423953D0 GB 0423953 A GB0423953 A GB 0423953A GB 0423953 D0 GB0423953 D0 GB 0423953D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical composition
composition containing
botulinum neurotoxin
containing botulinum
neurotoxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB0423953.9A
Other versions
GB2419527A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Ltd
Original Assignee
Ipsen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Ltd filed Critical Ipsen Ltd
Priority to GB0423953A priority Critical patent/GB2419527A/en
Publication of GB0423953D0 publication Critical patent/GB0423953D0/en
Priority to DK05767871.6T priority patent/DK1776137T3/en
Priority to ES05767871.6T priority patent/ES2526912T3/en
Priority to PT57678716T priority patent/PT1776137E/en
Priority to EP14180875.8A priority patent/EP2813239B1/en
Priority to ES05767945.8T priority patent/ES2526913T3/en
Priority to PCT/GB2005/003057 priority patent/WO2006013370A1/en
Priority to HUE14180875A priority patent/HUE032950T2/en
Priority to EP05767871.6A priority patent/EP1776137B1/en
Priority to EP05767945.8A priority patent/EP1778279B1/en
Priority to TR2017/08749T priority patent/TR201708749T4/en
Priority to PL14180875T priority patent/PL2813239T3/en
Priority to DK14180875.8T priority patent/DK2813239T3/en
Priority to US11/659,448 priority patent/US20080069841A1/en
Priority to PT141808758T priority patent/PT2813239T/en
Priority to EP17161071.0A priority patent/EP3210620A1/en
Priority to PCT/GB2005/003036 priority patent/WO2006013357A1/en
Priority to US11/659,449 priority patent/US20080102090A1/en
Priority to PL05767871T priority patent/PL1776137T3/en
Priority to ES14180875.8T priority patent/ES2627627T3/en
Publication of GB2419527A publication Critical patent/GB2419527A/en
Priority to US12/748,733 priority patent/US20100184689A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893Botulinum neurotoxin (3.4.24.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • A61K2201/06

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GB0423953A 2004-08-04 2004-10-28 Pharmaceutical composition containing botulinum neurotoxin Withdrawn GB2419527A (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
GB0423953A GB2419527A (en) 2004-10-28 2004-10-28 Pharmaceutical composition containing botulinum neurotoxin
ES14180875.8T ES2627627T3 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin A2
TR2017/08749T TR201708749T4 (en) 2004-08-04 2005-08-03 PHARMACEUTICAL COMPOSITION CONTAINING BOTULINUM NEUROTOXIN A2
DK14180875.8T DK2813239T3 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin A2
PT57678716T PT1776137E (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin a2
EP14180875.8A EP2813239B1 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin A2
ES05767945.8T ES2526913T3 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin 2
PCT/GB2005/003057 WO2006013370A1 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin a2
HUE14180875A HUE032950T2 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin A2
EP05767871.6A EP1776137B1 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin a2
EP05767945.8A EP1778279B1 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin a2
DK05767871.6T DK1776137T3 (en) 2004-08-04 2005-08-03 A pharmaceutical composition comprising botulinum neurotoxin A2
PL14180875T PL2813239T3 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin A2
ES05767871.6T ES2526912T3 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin A2
US11/659,448 US20080069841A1 (en) 2004-08-04 2005-08-03 Pharmaceutical Compositions Containing Botulinum Neurotoxin A2
PT141808758T PT2813239T (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin a2
EP17161071.0A EP3210620A1 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin a2
PCT/GB2005/003036 WO2006013357A1 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin a2
US11/659,449 US20080102090A1 (en) 2004-08-04 2005-08-03 Pharmaceutical Compositon Containing Botulinum Neurotoxin A2
PL05767871T PL1776137T3 (en) 2004-08-04 2005-08-03 Pharmaceutical composition containing botulinum neurotoxin a2
US12/748,733 US20100184689A1 (en) 2004-08-04 2010-03-29 Pharmaceutical Composition Containing Botulinum Neurotoxin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0423953A GB2419527A (en) 2004-10-28 2004-10-28 Pharmaceutical composition containing botulinum neurotoxin

Publications (2)

Publication Number Publication Date
GB0423953D0 true GB0423953D0 (en) 2004-12-01
GB2419527A GB2419527A (en) 2006-05-03

Family

ID=33515713

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0423953A Withdrawn GB2419527A (en) 2004-08-04 2004-10-28 Pharmaceutical composition containing botulinum neurotoxin

Country Status (1)

Country Link
GB (1) GB2419527A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113876936A (en) * 2021-11-09 2022-01-04 达尔文新研(北京)生物科技有限公司 High-stability botulinum toxin composition for injection and preparation method and application thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
AU2016204034B2 (en) * 2005-10-06 2017-12-21 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
EP2373294B1 (en) * 2008-12-10 2016-04-20 Allergan, Inc. Clostridial toxin pharmaceutical compositions
TW202247855A (en) 2016-09-13 2022-12-16 美商愛力根公司 Non-protein clostridial toxin compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030095927A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
EP1053014A4 (en) * 1998-01-26 2004-11-10 Univ Massachusetts $ I (CLOSTRIDIUM BOTULINUM) TYPE A BIOLOGICALLY ACTIVE HEMAGGLUTININ AND METHODS OF USE
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US20020197278A1 (en) * 2001-06-21 2002-12-26 Surromed, Inc. Covalent coupling of botulinum toxin with polyethylene glycol

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113876936A (en) * 2021-11-09 2022-01-04 达尔文新研(北京)生物科技有限公司 High-stability botulinum toxin composition for injection and preparation method and application thereof
CN113876936B (en) * 2021-11-09 2022-08-16 达尔文新研(北京)生物科技有限公司 High-stability botulinum toxin composition for injection and preparation method and application thereof

Also Published As

Publication number Publication date
GB2419527A (en) 2006-05-03

Similar Documents

Publication Publication Date Title
IL180380A0 (en) Pharmaceutical composition containing botulinum neurotoxin
IL225848A0 (en) Therapeutic composition with a botulinum neurotoxin
IL177480A0 (en) Pharmaceutical composition
PT1776137E (en) Pharmaceutical composition containing botulinum neurotoxin a2
ZA200708705B (en) Pharmaceutical composition
ZA200606154B (en) Pharmaceutical composition comprising pimobendan
GB0417367D0 (en) Pharmaceutical composition containing botulinum neurotoxin
HU0401177D0 (en) Pharmaceutical composition
GB0423952D0 (en) Pharmaceutical composition containing botulinum neurotoxin
GB2411355B (en) Pharmaceutical composition
GB0423953D0 (en) Pharmaceutical composition containing botulinum neurotoxin
GB0425255D0 (en) Pharmaceutical composition
ZA200701932B (en) Pharmaceutical composition
GB0421288D0 (en) Pharmaceutical composition containing botulinum neurotoxin
GB0423950D0 (en) Pharmaceutical composition containing botulinum neurotoxin
ZA200808768B (en) Pharmaceutical composition containing the NMB0606 protein
ZA200701931B (en) Pharmaceutical composition
GB0421290D0 (en) Pharmaceutical composition containing botulinum neurotoxin
ZA200805355B (en) Pharmaceutical compositions containing protein NMA0939
GB0402799D0 (en) Pharmaceutical composition
GB0425259D0 (en) Pharmaceutical composition
GB0425256D0 (en) Pharmaceutical composition
GB0518166D0 (en) Pharmaceutical composition
GB0511801D0 (en) Pharmaceutical composition
GB0504276D0 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)